PMID- 11023516
OWN - NLM
STAT- MEDLINE
DCOM- 20001109
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 96
IP  - 8
DP  - 2000 Oct 15
TI  - Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following 
      allogeneic stem cell transplantation.
PG  - 2814-21
AB  - Epstein-Barr virus (EBV)-specific CD8 T lymphocytes are present at remarkably 
      high frequencies in healthy EBV(+) individuals and provide protection from 
      EBV-associated lymphoproliferative diseases. Allogeneic peripheral blood stem 
      cell transplantation (allo-PBSCT) is a commonly used therapy in which T-cell 
      surveillance for EBV is temporarily disrupted. Herein, human leukocyte antigen 
      (HLA) class I tetramers were used to investigate the reestablishment of the 
      EBV-specific CD8 T-cell repertoire in patients following allo-PBSCT. CD8(+) T 
      cells specific for lytic and latent cycle-derived EBV peptides rapidly repopulate 
      the periphery of matched sibling allo-PBSCT patients. The relative frequencies of 
      T cells specific for different EBV peptides in transplantation recipients closely 
      reflect those of their respective donors. Investigation of patients at monthly 
      intervals following unmanipulated allo-PBSCT demonstrated that the frequency of 
      EBV-specific T cells correlates with the number of EBV genome copies in the 
      peripheral blood and that expansion of EBV-specific T-cell populations occurs 
      even in the setting of immunosuppressive therapy. In contrast, patients 
      undergoing T-cell-depleted or unrelated cord blood transplantation have 
      undetectable EBV-specific T cells, even in the presence of Epstein-Barr viremia. 
      The protective shield provided by EBV-specific CD8 T cells is rapidly established 
      following unmanipulated matched sibling allo-PBSCT and demonstrates that HLA 
      class I tetramers complexed with viral peptides can provide direct and rapid 
      assessment of pathogen-specific immunity in this and other vulnerable patient 
      populations. (Blood. 2000;96:2814-2821)
FAU - Marshall, N A
AU  - Marshall NA
AD  - Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
FAU - Howe, J G
AU  - Howe JG
FAU - Formica, R
AU  - Formica R
FAU - Krause, D
AU  - Krause D
FAU - Wagner, J E
AU  - Wagner JE
FAU - Berliner, N
AU  - Berliner N
FAU - Crouch, J
AU  - Crouch J
FAU - Pilip, I
AU  - Pilip I
FAU - Cooper, D
AU  - Cooper D
FAU - Blazar, B R
AU  - Blazar BR
FAU - Seropian, S
AU  - Seropian S
FAU - Pamer, E G
AU  - Pamer EG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antigens, Viral)
RN  - 0 (Biopolymers)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (HLA-B7 Antigen)
RN  - 0 (HLA-B8 Antigen)
RN  - 0 (Macromolecular Substances)
RN  - 0 (beta 2-Microglobulin)
SB  - IM
MH  - Adult
MH  - Antigen Presentation
MH  - Antigens, Viral/immunology
MH  - Biopolymers
MH  - CD8-Positive T-Lymphocytes/cytology/*immunology
MH  - Child
MH  - Epstein-Barr Virus Infections/immunology
MH  - Feasibility Studies
MH  - Female
MH  - Graft Survival
MH  - HLA-A2 Antigen/immunology
MH  - HLA-B7 Antigen/immunology
MH  - HLA-B8 Antigen/immunology
MH  - Hematologic Neoplasms/therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Herpesvirus 4, Human/*immunology/isolation & purification
MH  - Histocompatibility Testing
MH  - Humans
MH  - Kidney Transplantation
MH  - Lymphoproliferative Disorders/etiology/prevention & control/virology
MH  - Macromolecular Substances
MH  - Male
MH  - Middle Aged
MH  - T-Lymphocyte Subsets/cytology/*immunology
MH  - Tissue Donors
MH  - Transplantation Conditioning
MH  - Transplantation, Homologous/*immunology
MH  - Viral Load
MH  - beta 2-Microglobulin/immunology
EDAT- 2000/10/07 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/07 11:00
PHST- 2000/10/07 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/07 11:00 [entrez]
AID - S0006-4971(20)54317-6 [pii]
PST - ppublish
SO  - Blood. 2000 Oct 15;96(8):2814-21.